IASLC > International Association for the Study of Lung Cancer > Conferences & Events > Event Details
Radiotherapy Highlights from WCLC and ASTRO 2019
December 11, 2019 | Online


OVERVIEW: This webinar features two presentations followed by a question and answer session. Faculty will present a summary of key radiotherapy presentations from IASLC’s 2019 World Conference on Lung Cancer (WCLC) and 2019 American Society of Thoracic Radiation Oncology (ASTRO) annual meeting. The presentations will include Phase II and III clinical trials, advanced technologies (e.g. proton therapy) and clinical use of combination radiation and drug treatment.

TARGET AUDIENCE: This webinar is designed to meet the educational needs of radiation oncologists, clinical oncologists, medical physicists, therapy radiographers, advanced practice nurses, physician’s assistants and other healthcare professionals who diagnose and treat patients with lung cancer.

LEARNING OBJECTIVES: At the conclusion of this activity, the learner will be able to:

1. Discuss practice changing studies.
2. Identify advances in radiation technology.

Clinical Trials Integrating Immunotherapy and Radiation for Non–Small-Cell Lung Cancer
Daly, Megan E. et al.
Journal of Thoracic Oncology, Volume 10, Issue 12, 1685 - 1693 


Prof. Corinne Faivre-Finn, FRCR MD PhD
Professor of Thoracic Radiation Oncology
University of Manchester
Consultant Clinical Oncologist,
The Christie NHS Foundation Trust
Disclosure: No relevant financial relationships.

Radiotherapy Highlights from WCLC 2019

Professor Emerita,
Department of Radiation Oncology
University of Colorado
Radiation Oncologist, Banner MD Anderson in Northern Colorado
Disclosure: No relevant financial relationships.

Radiotherapy Highlights from ASTRO 2019

Andreas Rimner, MD
Associate Attending
Director of Thoracic Radiation Oncology Research
Department of Radiation Oncology
Memorial Sloan Kettering Cancer Center
New York
Disclosure: Varian Medical Systems (contracted support/research grant, advisory board); Boehringer Ingelheim (contracted support/research grant), Pfizer (contracted support/research grant) , AstraZeneca (contracted support/research grant, advisory board), Merck (contracted support/research grant, advisory board), Cybrexa (advisory Board), MoreHealth (consultant), Research to Practice (honorarium) and Philips/Elekta (travel support).


Member Experience Department